ELISA/assay

Human Cochlin (COCH) ELISA Kit

MBS7215472

48-Strip-Wells

470 USD

ELISA Kit

Human Cochlin (COCH) ELISA Kit

Cochlin (COCH)

cochlin; Cochlin; cochlin; coagulation factor C homolog, cochlin (Limulus polyphemus); cochlin; COCH-5B2

COCH

COCH; COCH; DFNA9; COCH5B2; COCH-5B2; COCH5B2; UNQ257/PRO294

COCH_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of COCH. No significant cross-reactivity or interference between COCH and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between COCH and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This COCH ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human COCH. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Neurobiology

Principle of the assay: COCH ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-COCH antibody and an COCH-HRP conjugate. The assay sample and buffer are incubated together with COCH-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the COCH concentration since COCH from samples and COCH-HRP conjugate compete for the anti-COCH antibody binding site. Since the number of sites is limited, as more sites are occupied by COCH from the sample, fewer sites are left to bind COCH-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The COCH concentration in each sample is interpolated from this standard curve.

205277471

NP_001128530.1

NM_001135058.1

59,483 Da

The protein encoded by this gene is highly conserved in human, mouse, and chicken, showing 94% and 79% amino acid identity of human to mouse and chicken sequences, respectively. Hybridization to this gene was detected in spindle-shaped cells located along nerve fibers between the auditory ganglion and sensory epithelium. These cells accompany neurites at the habenula perforata, the opening through which neurites extend to innervate hair cells. This and the pattern of expression of this gene in chicken inner ear paralleled the histologic findings of acidophilic deposits, consistent with mucopolysaccharide ground substance, in temporal bones from DFNA9 (autosomal dominant nonsyndromic sensorineural deafness 9) patients. Mutations that cause DFNA9 have been reported in this gene. Alternative splicing results in multiple transcript variants encoding the same protein. Additional splice variants encoding distinct isoforms have been described but their biological validities have not been demonstrated. [provided by RefSeq, Oct 2008]

COCH: Plays a role in the control of cell shape and motility in the trabecular meshwork. Defects in COCH are the cause of deafness autosomal dominant type 9 (DFNA9). DFNA9 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA9 is characterized by onset in the fourth or fifth decade of life and initially involves the high frequencies. Deafness is progressive and usually complete by the sixth decade. In addition to cochlear involvement, DFNA9 patients also exhibit a spectrum of vestibular dysfunctions. Penetrance of the vestibular symptoms is often incomplete, and some patients are minimally affected, whereas others suffer from severe balance disturbances and episodes of vertigo. Affected individuals have mucopolysaccharide depositions in the channels of the cochlear and vestibular nerves. These depositions apparently cause strangulation and degeneration of dendritic fibers. Protein type: Secreted, signal peptide; Secreted; Extracellular matrix. Chromosomal Location of Human Ortholog: 14q11.2-q13. Cellular Component: extracellular matrix; proteinaceous extracellular matrix. Molecular Function: collagen binding; protein binding. Biological Process: regulation of cell shape; sensory perception of sound; defense response to bacterium; positive regulation of innate immune response. Disease: Deafness, Autosomal Dominant 9

48-Strip-Wells

470 USD

96-Strip-Wells

675